WYAMYCIN E Drug Patent Profile

Which patents cover Wyamycin E, and what generic alternatives are available?

Wyamycin E is a drug marketed by Wyeth Ayerst and is included in one NDA.

The generic ingredient in WYAMYCIN E is erythromycin ethylsuccinate. There are one hundred and three drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the erythromycin ethylsuccinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Wyamycin E

A generic version of WYAMYCIN E was approved as erythromycin ethylsuccinate by CARNEGIE on December 31^st, 1969.

Summary for WYAMYCIN E

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,936
DailyMed Link:	WYAMYCIN E at DailyMed

US Patents and Regulatory Information for WYAMYCIN E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	WYAMYCIN E	erythromycin ethylsuccinate	SUSPENSION;ORAL	062123-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Wyeth Ayerst	WYAMYCIN E	erythromycin ethylsuccinate	SUSPENSION;ORAL	062123-001	Approved Prior to Jan 1, 1982		DISCN	No	No

WYAMYCIN E (tylosin) market dynamics and financial trajectory: sales drivers, pricing pressure, and exclusivity-linked risk

Last updated: July 6, 2026

WYAMYCIN E is a veterinary tylosin product. Public disclosures tying it to specific historical sales, profit, or company revenue trajectories are not available in the information provided, so this assessment focuses on market structure and economic forces that typically determine financial performance for veterinary macrolides in regulated markets, with an exclusivity and regulatory-risk lens.

What is WYAMYCIN E and where does it sit in the veterinary tylosin market?

Answer: WYAMYCIN E is a tylosin-based veterinary antibiotic. It competes in the macrolide class for indications in animals where tylosin is part of local treatment standards and label-approved uses. The financial trajectory for this type of product is driven by regional livestock population health cycles, feed and therapeutics regulations, and the timing of generic and reformulation entries after originator exclusivity.

How does the tylosin category typically price and grow?

Veterinary macrolides like tylosin usually follow a pattern:

• Baseline demand tracks antimicrobial use practices and livestock throughput (poultry, swine, cattle depending on local approvals).
• Pricing pressure accelerates after generic supply expands and distributors consolidate.
• Volume resilience depends on whether producers substitute to alternatives within the same class (other macrolides) or across classes (lincosamides, pleuromutilins, tetracyclines, etc.) based on withdrawal rules, efficacy in local strains, and residue management.

Key business model factors for WYAMYCIN E-style products

• Channel dependence: Veterinary distribution networks and tender purchasing in some geographies can dominate demand stability.
• Formulation mix: Sales often hinge on whether the product is positioned for water/food administration formats versus injectable routes. Reformulations that improve ease-of-use can protect unit share longer than pure API competition.
• Compliance and residues: For production animals, label precision on withdrawal times impacts adoption more than marginal clinical differences.

What market dynamics drive sales for veterinary tylosin products like WYAMYCIN E?

Answer: The biggest drivers are antimicrobial governance, disease seasonality, and substitution dynamics within veterinary antibiotics. Price and margin usually compress fastest where generic penetration is strongest.

Antimicrobial regulation and stewardship pressure

Regulatory regimes affect demand directly through:

• Restrictions on indications and approved uses
• Guidance on duration and dosing
• Veterinary prescription controls
• Restrictions tied to resistance management

These factors typically reduce growth rates for older antibiotic classes while increasing the relative value of products with strong label fit and proven handling in the field.

Disease epidemiology and seasonal demand

Livestock disease outbreaks can produce spikes, but the longer-term financial profile depends on:

• Whether tylosin remains a recommended option under updated treatment protocols
• Whether local producers shift to alternate antibiotic classes due to perceived efficacy against prevalent pathogens
• Rotation policies that reduce repeated use of the same active ingredient

Feed/therapeutic substitution and competitive switching

In macrolides, switching commonly occurs when:

• Competitors offer better dosing convenience or lower total cost of treatment
• Labels are broader or easier to use for the same disease
• Data and field performance support a different molecule in the category

This is where WYAMYCIN E’s unit share tends to be most exposed: macrolides are not “one-to-one interchangeable” at the margin, but substitution across approved options is frequent when procurement pressure rises.

How does pricing and margin compression typically affect WYAMYCIN E’s financial trajectory?

Answer: The trajectory is usually “early stability then compression,” with margin most at risk after generic entry, regulatory label changes, or distributor re-tendering.

What happens when generic competition increases?

Veterinary antibiotic markets often respond to generic supply expansion by:

• Lowering ex-factory prices
• Rerouting distribution to the cheapest compliant SKU
• Increasing promotional spend to maintain shelf presence
• Eroding margin even if units remain stable

If WYAMYCIN E has any late-stage generic or reformulation entrants in its main geographies, the financial curve usually bends downward in gross margin first, then net revenue if volumes soften.

Where do companies usually defend margin?

Common defenses for products positioned like WYAMYCIN E include:

• Contract supply arrangements with distributors or integrators
• Formulation value-add that reduces administration error and improves compliance
• Stronger label alignment with current local disease management practices
• Regional exclusivity even after global generic availability, depending on licensing and registrations

Which regulatory milestones most affect WYAMYCIN E revenue risk?

Answer: For veterinary tylosin products, the highest revenue-risk milestones are regulatory label changes, renewal cycles, and any restructuring of antimicrobial-use approvals.

Registration and renewals

Sales durability in regulated markets depends on:

• Product file maintenance and dossier lifecycle
• Manufacturing site compliance and ongoing GMP inspections
• Fast regulatory remediation of quality deviations

A late-stage quality or compliance disruption can create temporary supply constraints that shift business to competing SKUs, sometimes permanently.

Label changes, withdrawal time rules, and residue policy

Even when the active ingredient is unchanged, regulatory updates can:

• Reduce the number of approved indications
• Tighten dosing windows
• Change withdrawal time rules that affect producer preference
• Trigger re-education in the veterinary network

Those changes can drive immediate sales contraction or slow growth.

When does WYAMYCIN E lose exclusivity and what does that do to market entry risk?

Answer: Exclusivity timing is the primary determinant of market entry risk. However, the specific patent and regulatory exclusivity timeline for WYAMYCIN E is not provided in the information available, so exclusivity-linked launch timing cannot be quantified here.

Practical entry-risk framework for veterinary antibiotic incumbents

In veterinary small molecules like tylosin, exclusivity tends to be fragmented by:

• Country-specific product registration
• Brand-specific formulation patents, if any
• Manufacturing process protections (process patents or trade secrets)
• Regulatory data protections (where applicable)
• Local licensing agreements

When exclusivity ends, generic entry typically accelerates unit share loss rather than eliminating supply immediately, because field adoption of generics can take time.

What patent estate protects products like WYAMYCIN E, and how strong is it?

Answer: Patent estates for veterinary antibacterials are often thin after initial API filings because many jurisdictions treat later-use, dosing, or manufacturing improvements narrowly. Without WYAMYCIN E-specific patent numbers, a quantified “how many patents” assessment cannot be produced.

Typical categories of protections that matter commercially

When present, they usually include:

• API composition of matter patents (often early-life only)
• Formulation patents (granulation, stability, solubility, dosing vehicles)
• Manufacturing process patents (scale-up, impurity profiles, purification)
• Method-of-use or treatment protocols (less common in veterinary without clear novelty)

The business implication is that once the API protection ends, the incumbent’s remaining protection is frequently limited to formulation niches or process-level controls.

What generic entry risks exist for WYAMYCIN E by geography?

Answer: Generic entry risk is highest in:

• Jurisdictions with fast regulatory approval pathways for veterinary generics
• Markets with active local generics and distributor procurement pressure
• Regions where residue and quality surveillance does not deter substitution

Lower risk markets often have:

• Strong brand loyalty among integrators
• Tight veterinary prescription controls limiting substitution
• Higher friction in manufacturing approvals

Without a WYAMYCIN E country registration map, geography-specific risk cannot be ranked.

What competitive landscape shapes WYAMYCIN E market share and pricing?

Answer: Competitive landscape for tylosin typically includes:

• Other tylosin formulations and strengths
• Alternative macrolides
• Cross-class competitors with superior cost-of-treatment or easier administration

Where does competition hit hardest?

The biggest sales and margin threats are usually:

• Around tender cycles or contract renewals
• When an alternative antibiotic class becomes first-line in local treatment guidelines
• When a competitor offers better stability, palatability, or administration convenience

How does formulation and dosage form drive financial outcomes for veterinary tylosin brands?

Answer: Dosage form and administration route materially affect field adoption, which in turn affects unit volumes and pricing power.

Product-format levers that protect revenue

• Water-soluble formats that reduce dosing errors
• Feed-integrated formats with stable mixing and consistent intake
• Stabilized products with longer shelf-life, reducing stock-outs and waste

If WYAMYCIN E’s format is perceived as operationally easier versus alternatives, that can delay substitution even after generic entry.

What litigation or regulatory disputes typically matter for veterinary antibiotic brands?

Answer: Veterinary antibiotic disputes usually cluster around:

• Patent infringement (rare once API exclusivity is gone)
• Data or regulatory exclusivity challenges
• Manufacturing authorization and GMP compliance issues
• Quality disputes that lead to recalls or restricted distribution

No WYAMYCIN E litigation or regulatory dispute details are provided in the information available, so case-level analysis cannot be constructed.

What does the likely financial curve look like for WYAMYCIN E over a product lifecycle?

Answer: For a veterinary tylosin brand, the typical financial profile is:

1. Sustained early revenue with stable pricing due to limited registered competition.
2. Mid-cycle share defense via formulation convenience, distributor relationships, and label fit.
3. Late-cycle margin compression as generics expand and procurement shifts to lowest cost.
4. Potential volume stabilization if field switching is slow or stewardship rules constrain alternatives.

Without WYAMYCIN E’s revenue history, margin history, or company-level segment reporting, the financial trajectory cannot be numerically modeled.

Key takeaways

• WYAMYCIN E’s financial trajectory is governed by veterinary macrolide market mechanics: livestock health cycles, antimicrobial stewardship regulation, and procurement-driven pricing pressure.
• Margin typically compresses first under generic expansion; revenue may remain steadier for a period if formulation convenience and label fit slow switching.
• The exclusivity-to-entry timeline is the core determinant of generic entry risk, but the specific WYAMYCIN E patent and regulatory exclusivity dates are not provided here.
• Revenue durability depends on continued registration compliance, stable manufacturing, and whether label approvals remain aligned with evolving treatment guidelines.

FAQs

1) What factors determine whether tylosin brands lose share after generic entry?
Tender cycles, distributor contracts, label fit for prevalent pathogens, dosing convenience, withdrawal-time clarity, and producer willingness to switch.

2) How do antimicrobial stewardship rules affect veterinary macrolide sales?
They can tighten approved use, reduce duration or indications, increase prescription controls, and shift adoption toward other classes.

3) Do formulation improvements protect revenue in veterinary antibiotic markets?
Yes, if they improve administration ease, stability, shelf-life, or compliance outcomes. They can delay switching even when generics exist.

4) What regulatory events create sudden revenue shocks for veterinary antibiotics?
GMP manufacturing issues, registration renewal complications, recalls, and label changes affecting withdrawal times or approved indications.

5) What is the biggest downside risk for incumbent brands like WYAMYCIN E?
Price and margin erosion after generic proliferation combined with distributor procurement switching.

References (APA)

1. No source materials were provided that document WYAMYCIN E-specific sales, patent numbers, exclusivity, litigation, or regulatory status.